Additional Resources and Assistance

CareASSIST is here to help you get the information and support you need. In addition to the program offerings, you may also find the following downloads and online resources helpful.

CareASSIST Downloads

CareASSIST Application Download

CareASSIST Application

The CareASSIST application covers all aspects of the program: Access and Reimbursement, Financial Assistance, and Resource Support. Follow the directions on the form to apply, or call 1-833-WE+CARE (1-833-930-2273) to get started.

CareASSIST Brochure Download

CareASSIST Brochure

The CareASSIST brochure contains an overview of the program and its offerings.

CareASSIST Resource Navigation Flashcard Download

CareASSIST Resource Navigation Flashcard

An overview of potential sources of prescription assistance.

Online Resources

Certain patients may require information or assistance beyond what CareASSIST may offer. Below are links to external organizations that may be able to help, or you can call 1-833-WE+CARE (1-833-930-2273) to learn about alternate coverage options.

Learn about Medicaid in your state and if you may be eligible.

Learn about Medicare and prescription drug coverage, eligibility, and how to access the care you may need.

Patient Advocate Foundation

Find help for insurance and healthcare access problems.

Patient Access Network Foundation

Offers help and hope to people with chronic or life-threatening illnesses for whom cost limits access to breakthrough medical treatments.

American Cancer Society—MM     

American Cancer Society—NHL

The American Cancer Society’s mission is to save lives, celebrate lives, and lead the fight for a world without cancer.

Blood and Marrow Transplant Information Network (BMT InfoNet)

Dedicated to providing transplant patients, survivors, and their loved ones with emotional support and high-quality, easy-to-understand information about bone marrow, peripheral blood stem cell, and cord blood transplants.

The Bone Marrow Foundation

Offers financial assistance and free support services to bone marrow/stem cell transplant patients and their families.

Center for International Blood and Marrow Transplant Research

Dedicated to improving survival, treatment, and quality of life for transplant patients. With more than 1100 publications, the CIBMTR conducts practice-changing research that helps patients and physicians.

International Myeloma Foundation

The first and largest myeloma-specific charity in the world. With more than 525,000 members in 140 countries, the IMF serves myeloma patients, family members, and the medical community. The IMF provides a wide range of programs in the areas of research, education, support, and advocacy.

Leukemia and Lymphoma Society

The mission of The Leukemia & Lymphoma Society (LLS) is: cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS exists to find cures and ensure access to treatments for blood cancer patients. The LLS is the voice for all blood cancer patients, and works to ensure access to treatments for all blood cancer patients.

Lymphoma Research Foundation

The nation’s largest lymphoma-focused health organization devoted to improving care through education and support services and improving outcomes through investment in the most promising lymphoma research. Our mission is to eradicate lymphoma and serve all those impacted by this blood cancer.

Multiple Myeloma Research Foundation

Because its only motivation is to find a cure, it is unencumbered in its ability to identify the barriers to progress, develop models to overcome them, and help evolve the industry through technologies that foster collaboration and leverage the collective power of the entire community.

The Myeloma Beacon

Independent, up-to-date news and information for the multiple myeloma community.

National Bone Marrow Transplant Link (nbmtLINK)

Dedicated to helping individuals and their families from diagnosis through survivorship. It works with hospitals, cancer centers, and other organizations to reinforce and complement medical care. The nbmtLINK has been linking, curing, and caring since 1992, providing a number of services and resources designed to meet the needs of patients, survivors, caregivers, and health professionals around the country.

National Marrow Donor Program

Dedicated to helping every patient get the life-saving transplant they need. As a trusted leader in advancing treatments for those facing life-threatening blood cancers, it provides the groundbreaking research, innovative technology, patient support, and education that saves lives.


MOZOBIL® (plerixafor injection) is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM).


  • Severe, life-threatening allergic reactions (anaphylaxis) can happen in people who take Mozobil. Tell your doctor right away if you experience hives (itchy raised bumps), eye swelling, or trouble breathing.
  • Mozobil is not intended for hematopoietic stem cell transplantation (HSCT) mobilization and collection in patients with leukemia.
  • Mozobil in combination with G-CSF increases circulating white blood cells (WBCs). Your WBC counts will be monitored.
  • Thrombocytopenia (a decrease in the number of platelets circulating in the blood) has been observed in patients receiving Mozobil. Your platelet counts will be monitored.
  • Cancer cells may be released from the bone marrow and subsequently collected along with your stem cells during apheresis. The potential effects of infusing cancer cells during your transplant have not been well-studied.
  • Your spleen may be examined if you experience pain in the left upper stomach area or left shoulder area as these may be signs of an enlarged or burst (ruptured) spleen.
  • Mozobil can harm the unborn child when administered to a pregnant woman. Scientific studies have shown that Mozobil causes harm or death to unborn animals. If you are pregnant, your doctor should tell you about the potential risk to the fetus. If you are a female of childbearing potential you should use an effective form of contraception during treatment with Mozobil and for one week after the final dose.
  • Breastfeeding is not recommended during treatment with Mozobil and for one week after the final dose.
  • The most common adverse reactions (occurring in greater than or equal to 10% of patients) during HSC mobilization and apheresis were: diarrhea (37%), nausea (34%), tiredness (fatigue) (27%), injection site reactions (34%), headache (22%), pain in your joints (arthralgia) (13%), dizziness (11%), and vomiting (10%).